1. We believe the guidance provided in the introductory text to the listings and in SSR 14-3p is sufficient for evaluating endocrine disorders other than diabetes mellitus.
2. We believe the guidance provided in the introductory text to the listings and in SSR 14-2p is sufficient for evaluating diabetes mellitus. However, given that claimants with diabetes mellitus often have coexisting impairments, this may be a good opportunity to provide guidance on how we assess the combined effects of multiple non-severe impairments at step two of the sequential evaluation process.
3. We are unable to provide any comments on the use of pancreatic islet cell transplantation to treat people with type 1 diabetes.
4. We have not conducted any special studies in this area. Additionally, we are unaware of any problems with the proper interpretation of the endocrine listings or the evaluation of endocrine disorders.